Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-7888 in pediatric patients with relapsed or refractory high-grade gliomas
jRCT2080223161Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adegramotide + nelatimotide in high-grade glioma (HGG), glioblastoma (GBM), diffuse intrinsic pontine glioma (DIPG) and 1 more, sponsored by Sumitomo Pharma. Primary endpoint: Dose-limiting toxicities (DLTs) and safety of DSP-7888. Started Apr 2016; status: completed.
02
Drugs
adegramotide + nelatimotide
03
Conditions
high-grade glioma (HGG)glioblastoma (GBM)diffuse intrinsic pontine glioma (DIPG)glioma
Beyond the preview
Go deeper on jRCT2080223161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223161.